Harrow (HROW) Revenue Growth (3y) (2016 - 2026)
Harrow (HROW) Revenue Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 2.22% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 4.22% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.31% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.40% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 28.43% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.98% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | 28.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.28% |
| Mar 31, 2026 | 19.19% |
| Dec 31, 2025 | 63.65% |
| Sep 30, 2025 | 46.42% |
| Jun 30, 2025 | 39.81% |
| Mar 31, 2025 | 29.31% |
| Dec 31, 2024 | 49.04% |
| Sep 30, 2024 | 38.08% |
| Jun 30, 2024 | 39.23% |
| Mar 31, 2024 | 30.84% |
| Dec 31, 2023 | 35.56% |
| Sep 30, 2023 | 33.51% |
| Jun 30, 2023 | 60.73% |
| Mar 31, 2023 | 30.24% |
| Dec 31, 2022 | 17.27% |
| Sep 30, 2022 | 21.40% |
| Jun 30, 2022 | 19.94% |
| Mar 31, 2022 | 21.64% |
| Dec 31, 2021 | 21.04% |
| Sep 30, 2021 | 20.33% |